Hutchmed (china) Ltd revenue

Hutchmed (china) Ltd's revenue was $549m in fiscal 2025, down 13.0% on the year before. Since fiscal 2014 ($87.3m) it has grown at a compound 18.2% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Hutchmed (china) Ltd: revenue history, annual
Fiscal year	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	87	178	216	241	214	205	228	356	426	838	630	549
Growth on the year before	—	+104.1%	+21.3%	+11.6%	−11.2%	−4.3%	+11.3%	+56.2%	+19.7%	+96.5%	−24.8%	−13.0%
Gross profit	—	—	—	—	—	—	—	—	115	454	281	212
Gross margin	—	—	—	—	—	—	—	—	27.0%	54.1%	44.6%	38.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Hutchmed (china) Ltd	$549m	-13.0%	—
Adma Biologics, Inc.	$512m	8.0%	35.0%
Tarsus Pharmaceuticals, Inc.	$606m	105.2%	264.7%
Mirum Pharmaceuticals, Inc.	$618m	44.0%	74.8%
Krystal Biotech, Inc.	$470m	26.0%	280.1%
Arcutis Biotherapeutics, Inc.	$464m	76.1%	241.4%

Compare with peers

Head to head: ADMA vs HCM HCM vs TARS HCM vs MIRM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Hutchmed (china) Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Hutchmed (china) Ltd.